French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Upstream Bio (UPB) shares saw an increase in after-hours trading on Friday following the company's presentation of ...

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe ...

Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studiesAERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...

For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...

Type 2 inflammation, driven by IL-5, is a key factor in difficult-to-treat asthma and is present in up to 85% of CRSwNP cases. In the U.S., over 26 million people have asthma, leading to 100,000 ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...